CPT code 87511 – Gardnerella vaginalis amplified probe
87511 is the CPT code for infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, amplified probe technique. It applies when the lab detects G. vaginalis with a nucleic acid amplification test (NAAT), such as PCR or TMA.
Its sibling code 87510 covers the same organism by non-amplified probe. The methodology statement on the lab report decides which of the two codes goes on the claim.
- Section
- 80047-89398 Pathology and laboratory
- Subsection
- 87003-87999 Microbiology
- Code range
- 87468-87801 Infectious agent detection by nucleic acid (DNA or RNA)
- Billable
- No
- Code also known as
- BV NAAT, bacterial vaginosis PCR test, G. vaginalis DNA test, vaginal pathogen amplified probe
Let Pabau's smart automation suggest the right codes, reduce claim denials, and keep your practice compliant—effortlessly.
- AI-powered code suggestions
- Real-time compliance checks
- Faster claims, fewer denials
Automate repetitive tasks and focus on what matters most—your patients.
Reduce coding errors and ensure compliance with the latest regulations.
Clean claims, fewer denials, and faster reimbursements.
Powerful insights and reporting to help your practice thrive.
HIPAA compliant SOC 2 certified GDPR-compliant Trusted by 4,000+ clinics worldwide
Key takeaways
CPT 87511 covers detection of Gardnerella vaginalis DNA or RNA by an amplified method such as NAAT or PCR, not by non-amplified probe or culture.
Its sibling code 87510 covers the same organism by non-amplified probe, and billing both for one specimen triggers an NCCI edit.
N76.0 and N76.1 are the main ICD-10 pairings, while some MAC policies reject Z11.3 screening as the only diagnosis.
Each organism on a vaginal pathogen panel goes on its own claim line, such as 87481 for Candida and 87661 for Trichomonas.
Pabau, a practice management platform, checks eligibility and sends 837P claims through Claim.MD, so coverage problems show up before the swab is collected.
CPT Code 87511: Official descriptor and code structure
CPT Code 87511 describes infectious agent detection by nucleic acid (DNA or RNA) for Gardnerella vaginalis, using an amplified probe technique. The CPT Editorial Panel maintains the AMA’s CPT code set, which files 87511 among its organism-specific nucleic acid detection codes. Within that family, the amplification method is the main selection criterion.
The table below sets out how the code is built.
CPT 87511 covers only the organism-detection step. It does not capture a full bacterial vaginosis (BV) diagnosis, specimen collection or the physician’s interpretation. Specimen collection is billed separately where it applies.
Each analyte on a multi-organism vaginal panel goes on its own line under its own CPT code. Sexual health panels often combine 87511 with Candida and Trichomonas codes, and each line needs its own medical necessity documentation.
What CPT 87511 covers and what it excludes
CPT 87511 covers detection of Gardnerella vaginalis DNA or RNA by an amplified nucleic acid method only. The test must amplify the nucleic acid before detection. Without amplification, the code is 87510.
- Included: nucleic acid amplification test (NAAT), PCR, transcription-mediated amplification (TMA), strand displacement amplification (SDA), and other methods that amplify a target sequence.
- Excluded: non-amplified probe detection of Gardnerella vaginalis, which is billed with CPT 87510.
- Excluded: culture-based detection of Gardnerella vaginalis. Use 87081 for screening culture or 87070 for other-source culture, depending on method.
- Excluded: direct antigen or microscopy-based BV diagnosis.
- Excluded: the clinical BV diagnosis itself. Amsel criteria assessment is a clinical evaluation, not a molecular test.
- Excluded: specimen collection, which is billed separately with a collection code where applicable.
The amplified/non-amplified split is the most consequential distinction in this code family. Billing 87511 when the lab report confirms a hybridization-only method is overcoding, and it exposes the practice to audit liability. Check the lab’s methodology statement before you assign the code.
How the Gardnerella vaginalis nucleic acid test is performed and documented
CPT 87511 follows a fixed path from swab to result. Each step leaves a record that the chart must reflect.
- Specimen collection: the provider collects a vaginal swab, or the patient self-collects with an FDA-cleared kit. The chart must document collection date, specimen source and who collected it.
- Transport and accessioning: the swab goes to a CLIA-certified laboratory within the manufacturer’s stability window. The requisition must include the ordering provider’s NPI and the clinical indication.
- Nucleic acid extraction: the lab extracts DNA or RNA from the swab using a validated protocol. That protocol is tied to the specific FDA-cleared or laboratory-developed test in use.
- Amplification and detection: the extracted nucleic acid is amplified by PCR, TMA or an equivalent method, then detected with a probe or reporter system. The lab report names the platform, such as Hologic Aptima or BD MAX.
- Result reporting: the lab reports a positive, negative or indeterminate result for G. vaginalis. Keep this report in the patient record and reference it in the claim documentation.
The chart note must connect the clinical presentation to the test order. A note documenting abnormal vaginal discharge, odor or a pH abnormality justifies ordering an amplified NAAT. If the note says only “BV workup” with no clinical indicators, payer auditors have grounds to deny on medical necessity.
CPT 87511 vs. related codes: Choosing the right code
Most miscoding in this family comes from confusing amplified and non-amplified methods, or from billing the wrong organism code. The table below sets out the selection logic.
Bundling rule: National Correct Coding Initiative (NCCI) edits prohibit billing CPT 87511 and CPT 87510 together for the same specimen. The two codes describe different methods for the same organism, so billing both implies the specimen was tested twice. If the payer processes both, it will pay only the lower-valued code.
Check the current tables on the CMS NCCI edits page before submitting. The diagram below maps each lab method to the code it takes.

Pro Tip
Check the laboratory report’s methodology section before assigning 87510 or 87511. Lab reports from NAAT platforms (Hologic Aptima, BD MAX, Roche cobas) confirm amplified probe method. Reports from BD Affirm VPIII typically confirm non-amplified hybridization. When the method is ambiguous, call the reference lab before billing.
ICD-10 codes to pair with CPT 87511
Pairing CPT Code 87511 with the right ICD-10 code is what establishes medical necessity for the payer. Acute vaginitis, coded N76.0, is the pairing payers accept most widely. A code outside the payer’s accepted list is one of the top denial triggers for this CPT.
Confirm accepted pairings against your MAC’s Local Coverage Determination (LCD) for molecular diagnostic testing before submitting. The CMS Medicare Coverage Database lets you search each MAC’s LCDs and billing articles by CPT code.
Medicare reimbursement rates for CPT Code 87511
CPT Code 87511 is reimbursed under the Medicare Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. CMS administers the CLFS and updates it every January.
The national CLFS rate for 87511 has historically sat between about $14 and $20, and the exact figure changes with each annual update. Don’t rely on a static figure in any reference article, this one included. Check the current amount on the CMS Clinical Laboratory Fee Schedule page before you submit.
- Fee schedule type: Clinical Laboratory Fee Schedule (CLFS), not Physician Fee Schedule (PFS).
- Billing entity: the clinical laboratory performing the test bills CPT 87511, not the ordering physician.
- Geographic adjustment: CLFS rates are national rates. Unlike PFS rates, they carry no geographic practice cost index (GPCI) adjustment.
- Commercial payers: rates vary widely by contract. Some payers negotiate lab fee schedules separately from the CLFS.
- Rate updates: CMS publishes CLFS updates on its website, effective each January 1.
Payer coverage policies and prior authorization for CPT 87511
Coverage for CPT Code 87511 varies by payer, jurisdiction and clinical context. Medicare coverage is governed by MAC Local Coverage Determinations (LCDs), which define when molecular diagnostic tests are covered.
- MolDX Program: in MAC jurisdictions where Palmetto GBA or Noridian runs the MolDX program, NAAT codes must meet MolDX-specific coverage criteria. MolDX covers roughly half of Medicare beneficiaries. It may require test registration and coverage documentation beyond the standard LCD.
- Non-MolDX MACs: outside MolDX, coverage follows the MAC’s own LCD for molecular diagnostic testing. LCD requirements vary, so check the LCD for your jurisdiction.
- Medicaid: coverage varies by state. Some state programs follow Medicare LCD criteria, while others set their own. Ask the state Medicaid program for the applicable policy.
- Commercial payers: most major commercial plans cover amplified NAAT for Gardnerella vaginalis when medical necessity is documented. Most large payers don’t routinely require prior authorization for this code, but policies vary by plan.
- Screening versus diagnostic: some payers cover 87511 only for a symptomatic patient or abnormal findings, not for screening an asymptomatic patient. Using Z11.3 as the only ICD-10 code may trigger a non-covered-diagnosis denial in those plans.
Reviewing your medical billing compliance protocols before ordering molecular panels helps the practice document the clinical indication clearly. That is the most effective way to prevent coverage denials on 87511.
Medical necessity and clinical documentation requirements
Medical necessity for CPT Code 87511 depends on a chart note that gives a clinical reason for ordering an amplified NAAT over a cheaper alternative. Payers audit molecular diagnostic claims, and a vague chart note is the fastest route to a denial or a recoupment demand.
The chart note behind a 87511 claim should include these elements.
- Presenting symptoms: document abnormal vaginal discharge, malodor, pruritus or other clinical indicators. Amsel criteria findings strengthen the case for a molecular test: clue cells on wet mount, a fishy whiff test, elevated vaginal pH and homogeneous discharge.
- Reason for NAAT over non-amplified probe: where relevant, note why the amplified method was chosen. Higher analytical sensitivity, a prior negative with persistent symptoms, or the lab’s current platform are all valid reasons.
- Ordering provider credentials: the ordering provider must be licensed to order laboratory tests in the jurisdiction. The NPI must match the requisition.
- Specimen information: document specimen type, collection date and collection method in the chart. This supports chain-of-custody requirements if the claim is audited.
- Laboratory result: keep the CLIA-certified lab report in the patient record. It should name the test platform, the amplified probe method and whether the organism was detected.
Common denial reasons and how to appeal CPT 87511 claims
Most CPT Code 87511 denials fall into five categories, each with its own appeal approach. Effective denial management in healthcare starts with reading the denial reason code correctly before you draft an appeal.
When you appeal, send these four items together.
- A copy of the original claim with its remittance advice.
- The relevant chart note.
- The lab report confirming the test method.
- A short written statement citing the payer’s LCD or coverage policy.
The guide to medical billing denial codes maps each Claim Adjustment Reason Code (CARC) on the electronic remittance advice (ERA) to an appeal type. Tracking denials by code and payer then shows which documentation problems keep coming back.
Billing CPT Code 87511 on a vaginal pathogen panel
CPT Code 87511 is most often billed as one line on a multi-analyte vaginal pathogen panel. The other lines usually cover Candida with 87481 and Trichomonas vaginalis with 87661. No single bundled CPT code exists for a standard three-analyte vaginal panel, so each analyte is billed separately.
Candida also has a direct probe code, 87480, so the same method check applies to that line.
- Bill each organism separately: 87511 (Gardnerella), 87481 (Candida) and 87661 (Trichomonas) each go on their own claim line. Each line needs its own supporting diagnosis code.
- Separate medical necessity per analyte: payers expect a clinical reason for each organism tested. A chart note that says only “BV rule-out” may not support the Candida and Trichomonas lines.
- NCCI modifiers -59 and -XS: when two codes with an NCCI edit are both clinically indicated, modifier -59 can override the edit. So can its X-series equivalent, -XS (separate structure or specimen), for example when two specimens were collected. Use these modifiers only when the record supports separate testing events, because incorrect use is an audit trigger.
- MolDX panel registration: in MolDX jurisdictions, multi-analyte panels on FDA-cleared NAAT platforms may need registration in the MolDX system. Confirm registration status with the laboratory before billing.
Getting panel claims through as clean claims on the first pass takes accurate code selection, complete documentation and confirmed coverage for each analyte. Practices that run these panels often benefit from a standard order set. It maps each analyte to its CPT code and carries a documentation checklist for the ordering provider.
Pro Tip
Run a quarterly audit of your 87511, 87481, and 87661 claims together. Filter by denial reason code. NCCI bundling edits that cluster on specific dates usually point to one requisition. It pre-populates both 87511 and 87510 when a provider orders the panel. Update the order set to remove the non-amplified code if the lab only runs amplified methods.
How Pabau keeps CPT 87511 lab claims accurate
Lab claims like 87511 tend to break at three points: the eligibility check, the claim line and the remittance. Pabau, a practice management platform with built-in insurance billing, keeps all three on the patient record.
Before the swab is collected, the front desk runs an eligibility check through Claim.MD, Pabau’s US clearinghouse. Pabau’s claims management software then sends the 837P claim, with each analyte on its own line. ERA remittances come back against the same claim, so a denied 87511 line sits next to the record it came from.
Practices that switch on labs can also order Quest tests from the patient record, and the results import automatically. The order, the result and the claim then sit in one place when a payer asks for documentation.

Streamline your lab billing workflow
Pabau connects with Claim.MD to handle electronic claim submission, real-time eligibility checks, and ERA processing for CPT codes including 87511. See how practices reduce denials and speed up reimbursement.

Conclusion
Get the method right and the rest of an 87511 claim follows. Read the lab’s methodology statement before you code, because no ICD-10 pairing rescues a claim built on the wrong method.
The trade-off is effort up front. Building the method check and per-analyte documentation into your order set takes an afternoon. Fixing them after the denials arrive takes an appeal for every claim they touched.
Book a demo to see how Pabau keeps eligibility, panel claims and remittances on one record for your lab billing team.
Continue your research
Coding a noninflammatory vaginal disorder instead? ICD-10 code N89.8 covers other specified noninflammatory disorders of the vagina, a pairing some payers accept for 87511.
Seeing recurring denials on lab claims? Denial management in healthcare covers CARC-based workflows for finding and resolving claim rejections systematically.
Want to read denial codes off a lab remittance? Electronic remittance advice explains how ERA files carry denial reason codes back from payers for 87511 and similar lab codes.
Frequently asked questions
What does CPT Code 87511 cover?
CPT Code 87511 covers detection of Gardnerella vaginalis DNA or RNA by an amplified probe technique. It applies when a NAAT or PCR-based method tests a clinical specimen, typically a vaginal swab. It does not cover non-amplified probe testing (use 87510), culture methods or the clinical bacterial vaginosis diagnosis itself.
What is the difference between CPT 87510 and 87511?
CPT 87510 covers Gardnerella vaginalis detection by a non-amplified probe, using hybridization only. CPT 87511 covers detection by an amplified technique such as PCR or NAAT. The lab’s method decides which code applies. Billing both for the same specimen triggers an NCCI edit, so submit one code per specimen per organism.
What ICD-10 codes are paired with CPT 87511?
The most widely accepted pairings are N76.0 (acute vaginitis) and N76.1 (subacute and chronic vaginitis). Some payers accept N89.8 (other specified noninflammatory disorders of vagina). Z11.3 (encounter for screening for infections with a predominantly sexual mode of transmission) may fit a screening visit. Some MAC LCDs restrict 87511 to diagnostic use, so check your MAC’s current LCD first.
Does Medicare cover CPT Code 87511?
Yes. Medicare pays for CPT Code 87511 under the Clinical Laboratory Fee Schedule (CLFS). The claim needs documented medical necessity and must meet the MAC’s LCD criteria. MolDX jurisdictions (Palmetto GBA, Noridian) may add requirements such as test registration. A pure screening claim, with Z11.3 as the only diagnosis, may not be covered under some LCDs.



